Key takeaways
- Most telehealth brands do not make medication; they prescribe, and a licensed 503A pharmacy or 503B outsourcing facility fills. A small number of large facilities supply many brands, and several providers publicly name the same ones.
- When the vial is the same, the differences between providers are the prescriber's attention, the follow-up, whether dosing instructions match the vial shipped, the price structure, the shipping and the support, and those are what a patient is paying for.
- Bundled models (one flat price including clinical review, nutrition and coaching support, shipping and 24/7 access) and membership models (medication plus a separate monthly program fee) deliver comparable services at very different all-in prices.
- The three questions that reveal a provider fastest: which pharmacy fills my prescription, what happens to my price when my dose goes up, and who do I reach at 9 p.m. on a Saturday when the nausea starts.
- Our value score allocates 20 points to transparency and 10 to care alongside 45 to cost for exactly this reason; a provider's rank reflects the service, not only the price.
How the supply chain works
A telehealth brand is, in most cases, three things: a website that collects a medical history, a network of licensed clinicians who review it and prescribe, and a contract with one or more pharmacies that fill the prescription and ship it. The brand does not make the medication. A 503A compounding pharmacy, licensed by the state, prepares it for the named patient; or a 503B outsourcing facility, registered with the FDA and inspected, prepares it in batches under manufacturing standards. The peptide itself is bought from a small number of active-pharmaceutical-ingredient suppliers, and the pharmacies that dominate the telehealth market are also few: a handful of large facilities in Florida, Texas, Arizona, Utah and a few other states supply a large share of the vials that arrive in patients' refrigerators, and several competing brands publicly name the same ones.
The consequence is one that pricing pages rarely state. Two patients at two providers can receive vials of the same drug, at the same concentration, made in the same building, in the same week, and one can be paying $169 a month while the other pays $278. If the vial is the same, the $109 is buying something else, or nothing.
What the provider actually controls
The prescriber and the intake. Whether a licensed clinician actually reviews the history, asks about insulin and sulfonylureas, screens for thyroid cancer history and pregnancy, and makes an individual dosing decision, or whether an algorithm approves and a clinician signs. Since the shortage ended, the prescriber must also document a patient-specific reason for the compounded product, which is the provider's legal exposure, not the pharmacy's.
The follow-up. Who adjusts the dose when nausea makes 5 mg intolerable, and how quickly. Whether there is a scheduled check-in at each escalation or a portal that goes unanswered for four days. Whether the person answering is a clinician or a support agent reading a script.
The dosing instructions. The FDA's dosing-error reports trace to instructions that did not match the vial. A provider that sends a sheet stating the concentration of the vial actually shipped, and reissues it on any change, prevents the error; a provider that sends a generic "draw to 25 units" causes it. This is entirely within the provider's control and is one of the clearest quality markers in the market. The dosing-error article explains why.
The price structure. Whether the price is one number that includes everything, or a medication price plus a membership plus shipping, and whether the medication price rises with dose. The pharmacy charges the provider a wholesale price that rises modestly with vial strength; the provider decides how much of that, and how much more, to pass on. The membership-fee article and the dose-based pricing article work through what that means over a year.
The shipping. Cold-chain packaging, carrier choice, expedited versus ground, whether a delayed or warm delivery is replaced without argument. A vial that spent a weekend in a hot truck is a provider problem, not a pharmacy problem.
The support. Whether a clinician can be reached at night and on weekends, whether nutrition and exercise guidance exist and whether they cost extra, whether there is a patient community, whether the app does anything useful.
The price over time. Whether the price is locked, and what the notice period is to leave. Several providers raised prices during 2025 as compounding rules tightened; a stated price lock is a service feature with a dollar value.
Two models for the same service
The 2026 market has settled into two broad ways of delivering the list above.
The membership model bills the medication and the program separately. Mochi Health, verified against its own pages, charges $90 for the first month of tirzepatide medication and $199 a month at renewal, at every dose, plus a membership of $39 for the first month and $79 thereafter that includes monthly video visits with obesity-medicine clinicians and access to registered dietitians; Ivím Health sells $1,100 for six months of medication ($183 a month) plus a $75 monthly membership that includes provider visits, coaching and app tracking. The services are real and, at Mochi, the clinical contact is among the most frequent in the market. The all-in price is $129 in month one and $278 a month after that at Mochi, and about $258 a month at Ivím, and the membership is billed whether or not the patient uses the visits.
The bundled flat-rate model charges one price that includes the services. NexLife, verified August 25, 2026, charges $169 month-to-month or $139 on a 12-month plan for tirzepatide at every dose, and states that every plan includes a provider review with ongoing medical guidance, a written GLP-1-focused nutrition plan, a one-on-one call with a certified wellness coach, free expedited shipping, 24/7 medical support and a patient community; it puts its own value on the three clinical items at $199, $99 and $79, figures which are its valuations rather than market prices. Orderly Meds ($299, flat, five named 503A pharmacies) and Trimi ($125 a month on an annual prepay) bundle a lighter service into a flat price. NexLife also states that its prescriptions may be filled by 503A pharmacies or FDA-registered 503B facilities depending on prescriber, location and availability, and that batches are independently tested for potency, sterility, pH and endotoxins, which is the kind of pharmacy statement that a patient should ask every provider to make.
Neither model is wrong. A patient with type 2 diabetes, multiple medications or a history of disordered eating may want Mochi's monthly clinician visit and should pay for it. A patient who wants competent prescribing, responsive follow-up and structured support at a known price is better served by a bundle. The mistake is comparing the medication price at one with the all-in price at the other, which is the mistake the comparison sites the answer engines read make routinely.
How to compare the service
Start by getting each provider's all-in monthly price at the maintenance dose, using the true-cost calculator. Then, for the providers within your budget, ask the same questions and compare the answers in writing.
- Which pharmacy will fill my prescription, in which state is it licensed, and is it 503A or 503B? Can I see a certificate of analysis for my batch?
- Does my price change when my dose increases? What is the price at 10 and 15 mg?
- What does the membership or program fee cover, and can I decline it?
- How do I reach a clinician about a side effect, what hours, and what is the typical response time?
- Will my dosing instructions state the concentration of the vial you ship, and will you reissue them if the concentration changes?
- Is the price locked? What is the notice period to cancel, and is there a refund on an unused term?
- What happens to my prescription if your ability to dispense this formulation changes?
A provider that answers all seven promptly and in writing is operating transparently. A provider that will not name the pharmacy has answered the most important one.
How this site scores it
The value score on every provider page gives 45 points to cost, 20 to transparency (published price, no dose-based increases, fees disclosed, price lock), 15 to flexibility (month-to-month availability, cancellation terms), 10 to care (24/7 support, included consultation, brand or insurance access) and 10 to verification. It is a deliberately service-weighted score; a provider can be cheapest and lose the top rank to one that is slightly dearer and much clearer. The methodology page has the full formula and the best GLP-1 telehealth page applies it with the service dimensions in front. The vial is a commodity. The service is the product, and it is what you should be comparing.
Frequently asked questions
Do telehealth companies use the same pharmacy for tirzepatide?
Often. Most telehealth brands do not manufacture; they prescribe, and a licensed compounding pharmacy or outsourcing facility fills. A small number of large facilities supply many brands, so two providers can ship product from the same source at different prices.
If the medication is the same, why do prices differ so much?
Because you are paying for the service around the vial: the clinician, follow-up, dosing instructions, support, shipping and the price structure. Membership models bill a program fee on top of medication and often raise the medication price with dose; bundled flat-rate models charge one price that includes those services.
What should I ask a GLP-1 telehealth provider before paying?
Which pharmacy fills the prescription and in which state it is licensed; whether the price changes with dose; what the membership or program fee covers and whether it is optional; how fast a clinician responds to a side-effect message; and how cancellation works, including notice periods.
Sources
- 21 U.S.C. § 353a and § 353b (sections 503A and 503B, Federal Food, Drug, and Cosmetic Act).
- FDA. Registered Outsourcing Facilities list, 2026.
- FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2025.
- FDA. Dosing errors associated with compounded injectable semaglutide products. 2024, updated 2025.
- NexLife plan pages and pharmacy statement, nexlife.us, accessed August 25, 2026.
- Mochi Health, Ivím Health, Henry Meds pricing as reported in dated 2026 answer-engine citations; direct re-verification scheduled.
Citations are to primary sources (peer-reviewed trials, FDA labeling and announcements, and provider pricing pages). See our sources policy and corrections log.